Jeito Capital, prominent biotech investor, raises $1.2B for next fund

Summary: Jeito Capital, a major biotech investor, just raised a massive $1.2 billion fund. This money will help 15 to 20 early-stage drug companies in Europe grow and develop new medicines. Jeito focuses on treatments for cancer, obesity, eye problems, and autoimmune diseases. They have a great track record, having already helped build companies that were bought by giant drugmakers like Merck and Biogen. Even though overall funding for biotech startups has slowed down recently, Jeito is still making big moves to support new medical breakthroughs.

Source: rssapp-biopharmadive-com URL: biopharmadive.com/news/jeito-capital-biopharma-venture-fund-billion/816946/ (opens in new tab)